Bazedoxifene

Drug Profile

Bazedoxifene

Alternative Names: Bazedoxifene acetate; Bazedoxifeno; Conbriza; TSE-424; Viviant; WAY 140424

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals; Wyeth
  • Developer Almirall S.A.; Ligand Pharmaceuticals; Pfizer
  • Class Azepines; Calcium regulators; Indoles; Osteoporosis therapies; Phenols; Small molecules
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Postmenopausal osteoporosis

Most Recent Events

  • 07 Apr 2015 Bazedoxifene is still in Preregistration for Postmenopausal osteoporosis (Treatment and Prevention) in USA
  • 07 Apr 2015 Launched for Postmenopausal osteoporosis in Germany, Lithuania, Sweden, Croatia and Israel (PO) before April 2015
  • 24 Mar 2014 Bazedoxifine is still in the preregistration phase for approval in the treatment and prevention of Postmenopausal osteoarthritis in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top